Generation and in vitro functional characterization of anti-CD22 chimeric antigen receptor T cells derived from newly generated monoclonal antibody clones
Chimeric antigen receptor (CAR) T-cell therapy has transformed the treatment of B-cell malignancies, but relapse after CD19-directed therapy remains a major challenge, often because of loss or downregulation of CD19 expression. CD22 is an attractive alternative target because it is expressed on malignant B cells, inclu...